Copyright Reports & Markets. All rights reserved.

Global Human Tuberculosis Vaccine Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Human Tuberculosis Vaccine Consumption Value by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Intradermal
    • 1.3.3 Percutaneous
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Human Tuberculosis Vaccine Consumption Value by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Pediatrics
    • 1.4.3 Adults
  • 1.5 Global Human Tuberculosis Vaccine Market Size & Forecast
    • 1.5.1 Global Human Tuberculosis Vaccine Consumption Value (2020 & 2024 & 2031)
    • 1.5.2 Global Human Tuberculosis Vaccine Sales Quantity (2020-2031)
    • 1.5.3 Global Human Tuberculosis Vaccine Average Price (2020-2031)

2 Manufacturers Profiles

  • 2.1 GlaxoSmithKline
    • 2.1.1 GlaxoSmithKline Details
    • 2.1.2 GlaxoSmithKline Major Business
    • 2.1.3 GlaxoSmithKline Human Tuberculosis Vaccine Product and Services
    • 2.1.4 GlaxoSmithKline Human Tuberculosis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 GlaxoSmithKline Recent Developments/Updates
  • 2.2 Merck
    • 2.2.1 Merck Details
    • 2.2.2 Merck Major Business
    • 2.2.3 Merck Human Tuberculosis Vaccine Product and Services
    • 2.2.4 Merck Human Tuberculosis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 Merck Recent Developments/Updates
  • 2.3 Serum Institute of India
    • 2.3.1 Serum Institute of India Details
    • 2.3.2 Serum Institute of India Major Business
    • 2.3.3 Serum Institute of India Human Tuberculosis Vaccine Product and Services
    • 2.3.4 Serum Institute of India Human Tuberculosis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 Serum Institute of India Recent Developments/Updates
  • 2.4 Valneva
    • 2.4.1 Valneva Details
    • 2.4.2 Valneva Major Business
    • 2.4.3 Valneva Human Tuberculosis Vaccine Product and Services
    • 2.4.4 Valneva Human Tuberculosis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Valneva Recent Developments/Updates
  • 2.5 Archivel Farma
    • 2.5.1 Archivel Farma Details
    • 2.5.2 Archivel Farma Major Business
    • 2.5.3 Archivel Farma Human Tuberculosis Vaccine Product and Services
    • 2.5.4 Archivel Farma Human Tuberculosis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 Archivel Farma Recent Developments/Updates
  • 2.6 BIOFABRI (Zendal)
    • 2.6.1 BIOFABRI (Zendal) Details
    • 2.6.2 BIOFABRI (Zendal) Major Business
    • 2.6.3 BIOFABRI (Zendal) Human Tuberculosis Vaccine Product and Services
    • 2.6.4 BIOFABRI (Zendal) Human Tuberculosis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 BIOFABRI (Zendal) Recent Developments/Updates
  • 2.7 Japan BCG Laboratory
    • 2.7.1 Japan BCG Laboratory Details
    • 2.7.2 Japan BCG Laboratory Major Business
    • 2.7.3 Japan BCG Laboratory Human Tuberculosis Vaccine Product and Services
    • 2.7.4 Japan BCG Laboratory Human Tuberculosis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 Japan BCG Laboratory Recent Developments/Updates
  • 2.8 GreenSignal Bio Pharma
    • 2.8.1 GreenSignal Bio Pharma Details
    • 2.8.2 GreenSignal Bio Pharma Major Business
    • 2.8.3 GreenSignal Bio Pharma Human Tuberculosis Vaccine Product and Services
    • 2.8.4 GreenSignal Bio Pharma Human Tuberculosis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 GreenSignal Bio Pharma Recent Developments/Updates
  • 2.9 AJ Vaccines
    • 2.9.1 AJ Vaccines Details
    • 2.9.2 AJ Vaccines Major Business
    • 2.9.3 AJ Vaccines Human Tuberculosis Vaccine Product and Services
    • 2.9.4 AJ Vaccines Human Tuberculosis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.9.5 AJ Vaccines Recent Developments/Updates
  • 2.10 Taj Pharma India
    • 2.10.1 Taj Pharma India Details
    • 2.10.2 Taj Pharma India Major Business
    • 2.10.3 Taj Pharma India Human Tuberculosis Vaccine Product and Services
    • 2.10.4 Taj Pharma India Human Tuberculosis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.10.5 Taj Pharma India Recent Developments/Updates
  • 2.11 Biomed Lublin
    • 2.11.1 Biomed Lublin Details
    • 2.11.2 Biomed Lublin Major Business
    • 2.11.3 Biomed Lublin Human Tuberculosis Vaccine Product and Services
    • 2.11.4 Biomed Lublin Human Tuberculosis Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.11.5 Biomed Lublin Recent Developments/Updates

3 Competitive Environment: Human Tuberculosis Vaccine by Manufacturer

  • 3.1 Global Human Tuberculosis Vaccine Sales Quantity by Manufacturer (2020-2025)
  • 3.2 Global Human Tuberculosis Vaccine Revenue by Manufacturer (2020-2025)
  • 3.3 Global Human Tuberculosis Vaccine Average Price by Manufacturer (2020-2025)
  • 3.4 Market Share Analysis (2024)
    • 3.4.1 Producer Shipments of Human Tuberculosis Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2024
    • 3.4.2 Top 3 Human Tuberculosis Vaccine Manufacturer Market Share in 2024
    • 3.4.3 Top 6 Human Tuberculosis Vaccine Manufacturer Market Share in 2024
  • 3.5 Human Tuberculosis Vaccine Market: Overall Company Footprint Analysis
    • 3.5.1 Human Tuberculosis Vaccine Market: Region Footprint
    • 3.5.2 Human Tuberculosis Vaccine Market: Company Product Type Footprint
    • 3.5.3 Human Tuberculosis Vaccine Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Human Tuberculosis Vaccine Market Size by Region
    • 4.1.1 Global Human Tuberculosis Vaccine Sales Quantity by Region (2020-2031)
    • 4.1.2 Global Human Tuberculosis Vaccine Consumption Value by Region (2020-2031)
    • 4.1.3 Global Human Tuberculosis Vaccine Average Price by Region (2020-2031)
  • 4.2 North America Human Tuberculosis Vaccine Consumption Value (2020-2031)
  • 4.3 Europe Human Tuberculosis Vaccine Consumption Value (2020-2031)
  • 4.4 Asia-Pacific Human Tuberculosis Vaccine Consumption Value (2020-2031)
  • 4.5 South America Human Tuberculosis Vaccine Consumption Value (2020-2031)
  • 4.6 Middle East & Africa Human Tuberculosis Vaccine Consumption Value (2020-2031)

5 Market Segment by Type

  • 5.1 Global Human Tuberculosis Vaccine Sales Quantity by Type (2020-2031)
  • 5.2 Global Human Tuberculosis Vaccine Consumption Value by Type (2020-2031)
  • 5.3 Global Human Tuberculosis Vaccine Average Price by Type (2020-2031)

6 Market Segment by Application

  • 6.1 Global Human Tuberculosis Vaccine Sales Quantity by Application (2020-2031)
  • 6.2 Global Human Tuberculosis Vaccine Consumption Value by Application (2020-2031)
  • 6.3 Global Human Tuberculosis Vaccine Average Price by Application (2020-2031)

7 North America

  • 7.1 North America Human Tuberculosis Vaccine Sales Quantity by Type (2020-2031)
  • 7.2 North America Human Tuberculosis Vaccine Sales Quantity by Application (2020-2031)
  • 7.3 North America Human Tuberculosis Vaccine Market Size by Country
    • 7.3.1 North America Human Tuberculosis Vaccine Sales Quantity by Country (2020-2031)
    • 7.3.2 North America Human Tuberculosis Vaccine Consumption Value by Country (2020-2031)
    • 7.3.3 United States Market Size and Forecast (2020-2031)
    • 7.3.4 Canada Market Size and Forecast (2020-2031)
    • 7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe

  • 8.1 Europe Human Tuberculosis Vaccine Sales Quantity by Type (2020-2031)
  • 8.2 Europe Human Tuberculosis Vaccine Sales Quantity by Application (2020-2031)
  • 8.3 Europe Human Tuberculosis Vaccine Market Size by Country
    • 8.3.1 Europe Human Tuberculosis Vaccine Sales Quantity by Country (2020-2031)
    • 8.3.2 Europe Human Tuberculosis Vaccine Consumption Value by Country (2020-2031)
    • 8.3.3 Germany Market Size and Forecast (2020-2031)
    • 8.3.4 France Market Size and Forecast (2020-2031)
    • 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
    • 8.3.6 Russia Market Size and Forecast (2020-2031)
    • 8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific

  • 9.1 Asia-Pacific Human Tuberculosis Vaccine Sales Quantity by Type (2020-2031)
  • 9.2 Asia-Pacific Human Tuberculosis Vaccine Sales Quantity by Application (2020-2031)
  • 9.3 Asia-Pacific Human Tuberculosis Vaccine Market Size by Region
    • 9.3.1 Asia-Pacific Human Tuberculosis Vaccine Sales Quantity by Region (2020-2031)
    • 9.3.2 Asia-Pacific Human Tuberculosis Vaccine Consumption Value by Region (2020-2031)
    • 9.3.3 China Market Size and Forecast (2020-2031)
    • 9.3.4 Japan Market Size and Forecast (2020-2031)
    • 9.3.5 South Korea Market Size and Forecast (2020-2031)
    • 9.3.6 India Market Size and Forecast (2020-2031)
    • 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
    • 9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America

  • 10.1 South America Human Tuberculosis Vaccine Sales Quantity by Type (2020-2031)
  • 10.2 South America Human Tuberculosis Vaccine Sales Quantity by Application (2020-2031)
  • 10.3 South America Human Tuberculosis Vaccine Market Size by Country
    • 10.3.1 South America Human Tuberculosis Vaccine Sales Quantity by Country (2020-2031)
    • 10.3.2 South America Human Tuberculosis Vaccine Consumption Value by Country (2020-2031)
    • 10.3.3 Brazil Market Size and Forecast (2020-2031)
    • 10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa

  • 11.1 Middle East & Africa Human Tuberculosis Vaccine Sales Quantity by Type (2020-2031)
  • 11.2 Middle East & Africa Human Tuberculosis Vaccine Sales Quantity by Application (2020-2031)
  • 11.3 Middle East & Africa Human Tuberculosis Vaccine Market Size by Country
    • 11.3.1 Middle East & Africa Human Tuberculosis Vaccine Sales Quantity by Country (2020-2031)
    • 11.3.2 Middle East & Africa Human Tuberculosis Vaccine Consumption Value by Country (2020-2031)
    • 11.3.3 Turkey Market Size and Forecast (2020-2031)
    • 11.3.4 Egypt Market Size and Forecast (2020-2031)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
    • 11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics

  • 12.1 Human Tuberculosis Vaccine Market Drivers
  • 12.2 Human Tuberculosis Vaccine Market Restraints
  • 12.3 Human Tuberculosis Vaccine Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Human Tuberculosis Vaccine and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Human Tuberculosis Vaccine
  • 13.3 Human Tuberculosis Vaccine Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Human Tuberculosis Vaccine Typical Distributors
  • 14.3 Human Tuberculosis Vaccine Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Human Tuberculosis Vaccine market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global Human Tuberculosis Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Human Tuberculosis Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
    Global Human Tuberculosis Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
    Global Human Tuberculosis Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
    Global Human Tuberculosis Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Human Tuberculosis Vaccine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Human Tuberculosis Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GlaxoSmithKline, Merck, Serum Institute of India, Valneva, Archivel Farma, BIOFABRI (Zendal), Japan BCG Laboratory, GreenSignal Bio Pharma, AJ Vaccines, Taj Pharma India, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Human Tuberculosis Vaccine market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Intradermal
    Percutaneous
    Market segment by Application
    Pediatrics
    Adults
    Major players covered
    GlaxoSmithKline
    Merck
    Serum Institute of India
    Valneva
    Archivel Farma
    BIOFABRI (Zendal)
    Japan BCG Laboratory
    GreenSignal Bio Pharma
    AJ Vaccines
    Taj Pharma India
    Biomed Lublin
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Human Tuberculosis Vaccine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Human Tuberculosis Vaccine, with price, sales quantity, revenue, and global market share of Human Tuberculosis Vaccine from 2020 to 2025.
    Chapter 3, the Human Tuberculosis Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Human Tuberculosis Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Human Tuberculosis Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Human Tuberculosis Vaccine.
    Chapter 14 and 15, to describe Human Tuberculosis Vaccine sales channel, distributors, customers, research findings and conclusion.

    Buy now